Cardiac arrhythmia and immune response in COVID-19 patients
Main Article Content
Keywords
heart diseases, SARS-Cov2, arrhythmia, Immune response, Cytokine
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has presented substantial challenges for providing health care due to the numerous complications on the respiratory and cardiovascular systems of people. Cardiac arrhythmia is one of the cardiac complications, and it was observed in COVID-19 patients. Moreover, arrhythmia and cardiac arrest are common in COVID-19 patients in the intensive care unit. The occurrence of cardiac arrhythmia in COVID-19 patients is associated with hypoxia, cytokine storm, myocardial ischemia and inflammatory disease such as congestive heart failure. It is necessary to know the occurrence and mechanisms of tachyarrhythmia and bradyarrhythmia in patients with COVID-19 infection for their proper management. This review provides an overview of the association between COVID-19 and arrhythmias by detailing possible pathophysiological mechanisms.
References
1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke-statistics-2018 up-date: a report from the American Heart Association. Circulation. 2018;137(12):e67. 10.1161/CIR.0000000000000573
2. Fu D-G. Cardiac arrhythmias: diagnosis, symptoms, and treatments. Cell Biochem Biophys. 2015;73(2):291–296. 10.1007/s12013-015-0626-4
3. Behere SP, Weindling SN. Inherited arrhythmias: the cardiac channelopathies. Ann Pediatr Cardiol. 2015;8(3):210–220. 10.4103/0974-2069.164695
4. Lakkireddy DR, Chung MK, Deering TF, Gopinathannair R, Albert CM, Epstein LM, et al. Guidance for rebooting electrophysiology through the COVID-19 pandemic from the heart rhythm society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology. Circ Arrhythm Electrophysiol. 2020;13:e008999. 10.1016/j.hrthm.2020.06.012
5. Jee Y. WHO IHR emergency committee for the COVID-19 outbreak. Epidemiol Health. 2020;42:e2020013. 10.4178/epih.e2020013
6. COVID-19 United States cases by county. Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/us-map. (Accessed May 8, 2020).
7. Kochav SM, Coromilas E, Nalbandian A, et al. Cardiac arrhythmias in COVID-19 infection. Circ Arrhythm Electrophysiol 2020;13:e008719. 10.1161/CIRCEP.120.008719
8. Qu Z, Weiss JN. Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence. Ann Rev Physiol. 2015;77:29–55. 10.1146/annurev-physiol-021014-071622
9. Sato D, Xie LH, Sovari AA, Tran DX, Morita N, Xie F, et al. Synchronization of chaotic early afterdepolarizations in the genesis of cardiac arrhythmias. Proc Natl Acad Sci U S A. 2009;106:2983–2988. 10.1073/pnas.0809148106
10. Weiss JN, Garfinke A, Karagueuzian HS, Nguyen TP, Olcese R, Chen P-S, et al. Perspective: a dynamics-based classification of ventricular arrhythmias. J Mol Cell Cardiol. 2015;82:136–152. 10.1016/j.yjmcc.2015.02.017
11. Nasab EM, Athari SS. The first report of 2:1 atrioventricular block following COVID-19 vaccination. Clin Case Rep. 2022;10(5):e05797. 10.1002/ccr3.5797
12. Groleau G, et al. Complete heart block. J Emerg Med. 1986;4(1):25–32. 10.1016/0736-4679(86)90109-5
13. Nasab EM, Heidarzadeh S, Yavari B, Athari SS. Acute upper limb ischemia in a patient with COVID-19: a case report. Ann Vasc Surg. 2021;77:83–88. 10.1016/j.avsg.2021.07.007
14. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of covid-19 studies needed. N Engl J Med. 2020;382:1194–1196. 10.1056/NEJMp2002125
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. 10.1016/S0140-6736(20)30566-3
16. Rocca DGD, Magnocavallo M, Lavalle C, Romero J, Forleo GB, Tarantino N, et al. Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease. J Thromb Thrombolysis. 2021;51(3):571–576. 10.1007/s11239-020-02330-1
17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. 10.1001/jamacardio.2020.0950
18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5
19. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. 10.1001/jamacardio.2020.1017
20. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138-hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061. 10.1001/jama.2020.1585
21. He J, Wu B, Chen Y, Tang J, Liu Q, Zhou S, et al. Characteristic electrocardiographic manifestations in patients with COVID-19. Can J Cardiol. 2020;36(6):966.e1–966.e4. 10.1016/j.cjca.2020.03.028
22. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020;17:1439–1444. 10.1016/j.hrthm.2020.06.016
23. Berman JP, Abrams MP, Kushnir A, et al. Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. Indian Pacing Electrophysiol J. 2020;20:250–256. 10.1016/j.ipej.2020.08.006
24. Gopinathannair R, Merchant FM, Lakkireddy DR, Etheridge SP, Feigofsky S, Han JK, et al. COVID-19 and cardiac arrhythmias: a global perspective on ar-rhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020;59(2):329–336. 10.1007/s10840-020-00789-9
25. Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmaco-logical implications. J Cardiovasc Pharmacol. 2020;76(2):138–145. 10.1097/FJC.0000000000000854
26. Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol. 2020;43(7):796–802. 10.1002/clc.23384
27. Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in patients with COVID-19: a calm before the storm? Cureus. 2020;12:e8599. 10.7759/cureus.8599
28. Si D, Du B, Ni L, Yang B, Sun H, Jiang N, et al. Death, discharge and ar-rhythmias among patients with COVID-19 and cardiac injury. CMAJ. 2020;192(28):E791–E798. cmaj.200879. 10.1503/cmaj.200879
29. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol. 2005;28(11 Suppl 1):I3–I11. 10.1002/clc.4960281303
30. Manolis AS, et al. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med. 2020;30:451–460. 10.1016/j.tcm.2020.08.002
31. Singh AP, Tousif S, Umbarkar P, Lal H. A pharmacovigilance study of hydrox-ychloroquine cardiac safety profile: potential implication in COVID-19 mitiga-tion. J Clin Med. 2020;9:E1867. 10.3390/jcm9061867
32. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug inter-actions on QTc interval in exploratory COVID-19 treatment. J Am Coll Cardiol. 2020;75:2623–2624. 10.1016/j.jacc.2020.04.016
33. Yu C-M, Wong RS-M, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82:140–144. 10.1136/pgmj.2005.037515
34. Liu K, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin Med J (Engl). 2020;133:1025–1031. 10.1097/CM9.0000000000000744
35. Sala S, Peretto G, De Luca G, et al. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing Clin Electrophysiol. 2020;43(8):891–893. 10.1111/pace.13987
36. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–306. 10.1016/j.ijid.2014.09.003
37. Michael P, et al. Arrhythmias in the COVID-19 patient. Heart Rhythm Soc. 2022;3:8–14. 10.1016/j.hroo.2022.01.002
38. Azarkish M, Laleh Far V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J. 2020;41:2131. 10.1093/eurheartj/ehaa307
39. Kir D, Mohan C, Sancassani R. HEART BRAKEan unusual cardiac manifestation of coronavirus disease 2019 (COVID-19). J Am Coll Cardiol Case Rep. 2020;2:1252–1255.26. 10.1016/j.jaccas.2020.04.026
40. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;4(1):1798–1800. 10.1093/eurheartj/ehaa231
41. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31:1003–1008. 10.1111/jce.14479
42. Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723. 10.1016/j.lfs.2020.117723
43. Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, Tedrow U. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020;6(9):1193–1204. 10.1016/j.jacep.2020.08.002
44. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020;142: 7–9. 10.1161/CIRCULATIONAHA.120.047293
45. Kolettis TM. Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. Curr Opin Pharmacol. 2013;13: 210–217. 10.1016/j.coph.2013.01.001
46. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford). 2010;4(9):528–535. 10.1093/rheumatology/kep426
47. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63–64. 10.1038/s41577-018-0098-z
48. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015;2:26. 10.3389/fcvm.2015.00026
49. Lazzerini PE, Capecchi PL, Laghi-Pasini FM. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38:1717–1727. 10.1093/eurheartj/ehw208
50. Lazzerini PE, Acampa M, Capecchi PL, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res. 2015;67:332–339. 10.1002/acr.22455
51. Kobayashi H, Kobayashi Y, Yokoe I, Kitamura N, Nishiwaki A, Takei M, et al. Heart rate-corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab. J Rheumatol. 2018;45(12):1620–1627. 10.3899/jrheum.180065
52. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281–1285. 10.1001/jamacardio.2020.3551
53. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. 10.1126/science.abb2507
54. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–1659. 10.1056/NEJMsr2005760
55. Peretto G, Sala S, Rizzo S, et al. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2019;16:793–801. 10.1016/j.hrthm.2018.11.024
56. Zhang H, Park Y, Wu J, et al., Role of TNF-alpha in vascular dysfunction, Clin Sci (Lond.). 2009;116(3):219–230. 10.1042/CS20080196
57. Zhang G, Cai Q, Zhou H, He C, Chen Y, Zhang P, et al. OxLDL/β2GPI/anti β2GPI Ab complex induces inflammatory activation via the TLR4/NF κB pathway in HUVECs. Mol Med Rep. 2021;23(2):148. 10.3892/mmr.2020.11787
58. Waehre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109(16):1966–1972. 10.1161/01.CIR.0000125700.33637.B1
59. Kaptoge S, Seshasai SRK, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–589. 10.1093/eurheartj/eht367
60. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122(1):23–35. 10.1159/000338166
61. Bozorgi A, Nasab EM. Red cell distribution width and severe left ventricular dysfunction in ischemic heart failure. Crit Pathways Cardiol. 2016;15(4):174–178. 10.1097/HPC.0000000000000094
62. Nasab EM, Makoei RH, Aghajani H, Athari SS. IL-33/ST2 pathway as upper-hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure. ESC Heart Fail. 2022;9(6):3785–3790. 10.1002/ehf2.14111
63. Hami M, Naddaf S, Mobedi I, Zare-Bidaki M, Athari S, Hajimohammadi B, et al. Prevalence of Linguatula serrata infection in domestic bovids slaughtered in Tabriz Abattoir, Iran. Iran J Parasitol. 2009;4(3):25–31.
64. Klok FA, Kruip MJH, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. 10.1016/j.thromres.2020.04.013
65. Nasab EM, Heidarzadeh S, Athari SS. Right atrial clot and pulmonary embolism in a patient with COVID-19: a case report. Radiol Case Rep. 2021;16(11):3392–3395. 10.1016/j.radcr.2021.08.015
66. Nasab EM, Athari SS. COVID-19 cytokine storm complications in asthmatic patients. Open Public Health J. 2020;13:625–626. 10.2174/1874944502013010625
67. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: pathogenesis, prognosis and management. Arrhythm Electrophysiol Rev. 2018;7:43–48. 10.15420/aer.2018.3.2
68. Ñamendys-Silva SA, Santos-Martínez LE, Pulido T, et al. Pulmonary hypertension due to acute respiratory distress syndrome. Braz J Med Biol Res. 2014;47:904–910. 10.1590/1414-431X20143316
69. Seecheran R, Narayansingh R, Giddings S, et al. Atrial arrhythmias in a patient presenting with coronavirus-disease-2019 (COVID-19) infection. J Investig Med High Impact Case Rep. 2020;8:2324709620925571. 10.1177/2324709620925571
70. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. 10.1038/s41467-021-22781-1
71. Surawicz B. Role of electrolytes in etiology and management of cardiac arrhythmias. Prog Cardiovasc Dis. 1966;8:364–386. 10.1016/S0033-0620(66)80011-7
72. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213–1221. 10.1016/j.mayocp.2020.03.024
73. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–1041. 10.1001/jamacardio.2020.1834
74. Sun Y, Pavey H, Wilkinson I, Fisk M. Role of the IL-33/ST2 axis in cardiovascular disease: a systematic review and meta--analysis. PLoS One. 2021;16(11):e0259026. 10.1371/journal.pone.0259026
2. Fu D-G. Cardiac arrhythmias: diagnosis, symptoms, and treatments. Cell Biochem Biophys. 2015;73(2):291–296. 10.1007/s12013-015-0626-4
3. Behere SP, Weindling SN. Inherited arrhythmias: the cardiac channelopathies. Ann Pediatr Cardiol. 2015;8(3):210–220. 10.4103/0974-2069.164695
4. Lakkireddy DR, Chung MK, Deering TF, Gopinathannair R, Albert CM, Epstein LM, et al. Guidance for rebooting electrophysiology through the COVID-19 pandemic from the heart rhythm society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology. Circ Arrhythm Electrophysiol. 2020;13:e008999. 10.1016/j.hrthm.2020.06.012
5. Jee Y. WHO IHR emergency committee for the COVID-19 outbreak. Epidemiol Health. 2020;42:e2020013. 10.4178/epih.e2020013
6. COVID-19 United States cases by county. Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/us-map. (Accessed May 8, 2020).
7. Kochav SM, Coromilas E, Nalbandian A, et al. Cardiac arrhythmias in COVID-19 infection. Circ Arrhythm Electrophysiol 2020;13:e008719. 10.1161/CIRCEP.120.008719
8. Qu Z, Weiss JN. Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence. Ann Rev Physiol. 2015;77:29–55. 10.1146/annurev-physiol-021014-071622
9. Sato D, Xie LH, Sovari AA, Tran DX, Morita N, Xie F, et al. Synchronization of chaotic early afterdepolarizations in the genesis of cardiac arrhythmias. Proc Natl Acad Sci U S A. 2009;106:2983–2988. 10.1073/pnas.0809148106
10. Weiss JN, Garfinke A, Karagueuzian HS, Nguyen TP, Olcese R, Chen P-S, et al. Perspective: a dynamics-based classification of ventricular arrhythmias. J Mol Cell Cardiol. 2015;82:136–152. 10.1016/j.yjmcc.2015.02.017
11. Nasab EM, Athari SS. The first report of 2:1 atrioventricular block following COVID-19 vaccination. Clin Case Rep. 2022;10(5):e05797. 10.1002/ccr3.5797
12. Groleau G, et al. Complete heart block. J Emerg Med. 1986;4(1):25–32. 10.1016/0736-4679(86)90109-5
13. Nasab EM, Heidarzadeh S, Yavari B, Athari SS. Acute upper limb ischemia in a patient with COVID-19: a case report. Ann Vasc Surg. 2021;77:83–88. 10.1016/j.avsg.2021.07.007
14. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of covid-19 studies needed. N Engl J Med. 2020;382:1194–1196. 10.1056/NEJMp2002125
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. 10.1016/S0140-6736(20)30566-3
16. Rocca DGD, Magnocavallo M, Lavalle C, Romero J, Forleo GB, Tarantino N, et al. Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease. J Thromb Thrombolysis. 2021;51(3):571–576. 10.1007/s11239-020-02330-1
17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. 10.1001/jamacardio.2020.0950
18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5
19. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. 10.1001/jamacardio.2020.1017
20. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138-hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061. 10.1001/jama.2020.1585
21. He J, Wu B, Chen Y, Tang J, Liu Q, Zhou S, et al. Characteristic electrocardiographic manifestations in patients with COVID-19. Can J Cardiol. 2020;36(6):966.e1–966.e4. 10.1016/j.cjca.2020.03.028
22. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020;17:1439–1444. 10.1016/j.hrthm.2020.06.016
23. Berman JP, Abrams MP, Kushnir A, et al. Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. Indian Pacing Electrophysiol J. 2020;20:250–256. 10.1016/j.ipej.2020.08.006
24. Gopinathannair R, Merchant FM, Lakkireddy DR, Etheridge SP, Feigofsky S, Han JK, et al. COVID-19 and cardiac arrhythmias: a global perspective on ar-rhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020;59(2):329–336. 10.1007/s10840-020-00789-9
25. Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmaco-logical implications. J Cardiovasc Pharmacol. 2020;76(2):138–145. 10.1097/FJC.0000000000000854
26. Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol. 2020;43(7):796–802. 10.1002/clc.23384
27. Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in patients with COVID-19: a calm before the storm? Cureus. 2020;12:e8599. 10.7759/cureus.8599
28. Si D, Du B, Ni L, Yang B, Sun H, Jiang N, et al. Death, discharge and ar-rhythmias among patients with COVID-19 and cardiac injury. CMAJ. 2020;192(28):E791–E798. cmaj.200879. 10.1503/cmaj.200879
29. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol. 2005;28(11 Suppl 1):I3–I11. 10.1002/clc.4960281303
30. Manolis AS, et al. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med. 2020;30:451–460. 10.1016/j.tcm.2020.08.002
31. Singh AP, Tousif S, Umbarkar P, Lal H. A pharmacovigilance study of hydrox-ychloroquine cardiac safety profile: potential implication in COVID-19 mitiga-tion. J Clin Med. 2020;9:E1867. 10.3390/jcm9061867
32. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug inter-actions on QTc interval in exploratory COVID-19 treatment. J Am Coll Cardiol. 2020;75:2623–2624. 10.1016/j.jacc.2020.04.016
33. Yu C-M, Wong RS-M, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82:140–144. 10.1136/pgmj.2005.037515
34. Liu K, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin Med J (Engl). 2020;133:1025–1031. 10.1097/CM9.0000000000000744
35. Sala S, Peretto G, De Luca G, et al. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing Clin Electrophysiol. 2020;43(8):891–893. 10.1111/pace.13987
36. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–306. 10.1016/j.ijid.2014.09.003
37. Michael P, et al. Arrhythmias in the COVID-19 patient. Heart Rhythm Soc. 2022;3:8–14. 10.1016/j.hroo.2022.01.002
38. Azarkish M, Laleh Far V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J. 2020;41:2131. 10.1093/eurheartj/ehaa307
39. Kir D, Mohan C, Sancassani R. HEART BRAKEan unusual cardiac manifestation of coronavirus disease 2019 (COVID-19). J Am Coll Cardiol Case Rep. 2020;2:1252–1255.26. 10.1016/j.jaccas.2020.04.026
40. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;4(1):1798–1800. 10.1093/eurheartj/ehaa231
41. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31:1003–1008. 10.1111/jce.14479
42. Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723. 10.1016/j.lfs.2020.117723
43. Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, Tedrow U. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020;6(9):1193–1204. 10.1016/j.jacep.2020.08.002
44. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020;142: 7–9. 10.1161/CIRCULATIONAHA.120.047293
45. Kolettis TM. Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. Curr Opin Pharmacol. 2013;13: 210–217. 10.1016/j.coph.2013.01.001
46. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford). 2010;4(9):528–535. 10.1093/rheumatology/kep426
47. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63–64. 10.1038/s41577-018-0098-z
48. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015;2:26. 10.3389/fcvm.2015.00026
49. Lazzerini PE, Capecchi PL, Laghi-Pasini FM. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38:1717–1727. 10.1093/eurheartj/ehw208
50. Lazzerini PE, Acampa M, Capecchi PL, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res. 2015;67:332–339. 10.1002/acr.22455
51. Kobayashi H, Kobayashi Y, Yokoe I, Kitamura N, Nishiwaki A, Takei M, et al. Heart rate-corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab. J Rheumatol. 2018;45(12):1620–1627. 10.3899/jrheum.180065
52. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281–1285. 10.1001/jamacardio.2020.3551
53. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. 10.1126/science.abb2507
54. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–1659. 10.1056/NEJMsr2005760
55. Peretto G, Sala S, Rizzo S, et al. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2019;16:793–801. 10.1016/j.hrthm.2018.11.024
56. Zhang H, Park Y, Wu J, et al., Role of TNF-alpha in vascular dysfunction, Clin Sci (Lond.). 2009;116(3):219–230. 10.1042/CS20080196
57. Zhang G, Cai Q, Zhou H, He C, Chen Y, Zhang P, et al. OxLDL/β2GPI/anti β2GPI Ab complex induces inflammatory activation via the TLR4/NF κB pathway in HUVECs. Mol Med Rep. 2021;23(2):148. 10.3892/mmr.2020.11787
58. Waehre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109(16):1966–1972. 10.1161/01.CIR.0000125700.33637.B1
59. Kaptoge S, Seshasai SRK, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–589. 10.1093/eurheartj/eht367
60. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122(1):23–35. 10.1159/000338166
61. Bozorgi A, Nasab EM. Red cell distribution width and severe left ventricular dysfunction in ischemic heart failure. Crit Pathways Cardiol. 2016;15(4):174–178. 10.1097/HPC.0000000000000094
62. Nasab EM, Makoei RH, Aghajani H, Athari SS. IL-33/ST2 pathway as upper-hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure. ESC Heart Fail. 2022;9(6):3785–3790. 10.1002/ehf2.14111
63. Hami M, Naddaf S, Mobedi I, Zare-Bidaki M, Athari S, Hajimohammadi B, et al. Prevalence of Linguatula serrata infection in domestic bovids slaughtered in Tabriz Abattoir, Iran. Iran J Parasitol. 2009;4(3):25–31.
64. Klok FA, Kruip MJH, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. 10.1016/j.thromres.2020.04.013
65. Nasab EM, Heidarzadeh S, Athari SS. Right atrial clot and pulmonary embolism in a patient with COVID-19: a case report. Radiol Case Rep. 2021;16(11):3392–3395. 10.1016/j.radcr.2021.08.015
66. Nasab EM, Athari SS. COVID-19 cytokine storm complications in asthmatic patients. Open Public Health J. 2020;13:625–626. 10.2174/1874944502013010625
67. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial arrhythmias in pulmonary hypertension: pathogenesis, prognosis and management. Arrhythm Electrophysiol Rev. 2018;7:43–48. 10.15420/aer.2018.3.2
68. Ñamendys-Silva SA, Santos-Martínez LE, Pulido T, et al. Pulmonary hypertension due to acute respiratory distress syndrome. Braz J Med Biol Res. 2014;47:904–910. 10.1590/1414-431X20143316
69. Seecheran R, Narayansingh R, Giddings S, et al. Atrial arrhythmias in a patient presenting with coronavirus-disease-2019 (COVID-19) infection. J Investig Med High Impact Case Rep. 2020;8:2324709620925571. 10.1177/2324709620925571
70. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021;12(1):2506. 10.1038/s41467-021-22781-1
71. Surawicz B. Role of electrolytes in etiology and management of cardiac arrhythmias. Prog Cardiovasc Dis. 1966;8:364–386. 10.1016/S0033-0620(66)80011-7
72. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213–1221. 10.1016/j.mayocp.2020.03.024
73. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–1041. 10.1001/jamacardio.2020.1834
74. Sun Y, Pavey H, Wilkinson I, Fisk M. Role of the IL-33/ST2 axis in cardiovascular disease: a systematic review and meta--analysis. PLoS One. 2021;16(11):e0259026. 10.1371/journal.pone.0259026
Article Sidebar
Published
Jul 1, 2023
Article Details
How to Cite
Wang, C., & Hao, W. (2023). Cardiac arrhythmia and immune response in COVID-19 patients. Allergologia Et Immunopathologia, 51(4), 63-70. https://doi.org/10.15586/aei.v51i4.883
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Wang, C., & Hao, W. (2023). Cardiac arrhythmia and immune response in COVID-19 patients. Allergologia Et Immunopathologia, 51(4), 63-70. https://doi.org/10.15586/aei.v51i4.883